Abstracts Archive - Page 2201 of 2607 - ACR Meeting Abstracts

Abstract Number: 494 • 2014 ACR/ARHP Annual Meeting
Estimation of Cost per Effectively Treated Patients with Biologic Disease Modifying Anti-Rheumatic Drugs in US Veterans with Rheumatoid Arthritis
Grant W. Cannon¹, Chia-Chen Teng², Tao He², Jianwei Leng³, Chao-Chin Lu², Derek Tang⁴, Neel Shah⁵, David J. Harrison⁴ and Brian Sauer², ¹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Salt Lake City VA and University of Utah, Salt Lake City, UT, ³Salt Lake City VA and University of Utah, Salt Lake Citty, UT, ⁴Amgen Inc., Thousand Oaks, CA, ⁵1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA
Background/Purpose: An algorithm based on administrative claims data (in lieu of clinical measures) was validated using data from the Veteran’s Affairs (VA) Rheumatoid Arthritis (RA)…
Abstract Number: 493 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib Following Inadequate Response to Nonbiologic DMARD or Biologic DMARD
C. Charles-Schoeman¹, Gerd Burmester², P. Nash³, C.a.F. Zerbini⁴, S. Anway⁵, K. Kwok⁶, T. Hendrikx⁷, E. Bananis⁸ and Roy Fleischmann⁹, ¹University of California, Los Angeles, CA, ²Charité – University Medicine Berlin, Berlin, Germany, ³Rheumatology Research Unit, Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁴Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer BV, Capelle aan den IJssel, Netherlands, ⁸Pfizer Inc, Collegeville, PA, ⁹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we compare the efficacy and safety of tofacitinib 5…
Abstract Number: 492 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes from a Canadian Study of Patients Taking Methotrexate and Etanercept
J. Carter Thorne¹, Edward C. Keystone², Janet E. Pope³, Melanie Poulin-Costello⁴, Krystene Phan-Chronis⁵ and Boulos Haraoui⁶, ¹Southlake Regional Health Centre, Newmarket, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³St Joseph Health Care, London, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Amgen Canada Inc., Mississauga, ON, Canada, ⁶Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: The Canadian Methotrexate and Etanercept Outcome Study (CAMEO) evaluated etanercept (ETN) monotherapy vs ETN plus methotrexate (MTX) in biologic-naïve patients with rheumatoid arthritis…
Abstract Number: 491 • 2014 ACR/ARHP Annual Meeting
Do Patients with Congestive Heart Failure Treated with Biologics for RA Have a Lower Risk of Fatal Outcome of Serious Infections?
Anja Strangfeld¹, Adrian Richter¹, Yvette Meissner¹, Matthias Schneider², Michael Zaenker³, Wolfgang Ochs⁴, Thomas Klopsch⁵, Angela Zink⁶ and Joachim Listing¹, ¹German Rheumatism Research Center, Berlin, Germany, ²Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ³Immanuel Klinikum Bernau, Rheumatology Center Northern Brandenburg, Bernau, Germany, ⁴Rheumatologist in private practice, Bayreuth, Germany, ⁵Rheumatologist in private practice, Neubrandenburg, Germany, ⁶German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: Patients with multimorbid conditions are at high risk of developing serious infections (SI) and of premature mortality. TNF inhibitors increase the infection risk (1)…
Abstract Number: 490 • 2014 ACR/ARHP Annual Meeting
A Randomised Controlled Trial Evaluating the Effect of Humira upon Endothelial Function in ACPA Positive Rheumatoid Arthritis â€“ an Interim Analysis
Stephen Oakley^1,2,3, Niloofar Esmaili⁴, Gabor Major⁴, David Mathers^4,5, Siva Ratnarajah⁶, John van der Kallen⁵, Mark Collins⁶, Marc Toh⁶ and John Glass⁴, ¹Dept of Rheumatology, Newcastle Bone & Joint Institute, Newcastle, Australia, ²School of Medicine & Public Health, University of Newcastle, Newcastle, Australia, ³Clinical Trials Unit, Hunter Medical Research Institute, Newcastle, Australia, ⁴Rheumatology, Newcastle Bone & Joint Institute, Newcastle, Australia, ⁵Rheumatology, Georgetown Arthritis Centre, Newcastle, Australia, ⁶Rheumatology, Private Practice, Newcastle, Australia
Background/Purpose Rheumatoid arthritis (RA) is associated with elevated cardiovascular (CV) risk not explained by traditional risk factors. Increased CV risk may develop prior to the…
Abstract Number: 488 • 2014 ACR/ARHP Annual Meeting
Increases in Serum Cholesterol with Baricitinib Treatment Are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis
Joel M. Kremer¹, Mark C Genovese², Edward C. Keystone³, Peter C. Taylor⁴, Steven H. Zuckerman⁵, Douglas E. Schlichting⁵, Eric P. Nantz⁵, Scott D. Beattie⁵ and William L. Macias⁶, ¹Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ²Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ³University of Toronto, Toronto, ON, Canada, ⁴NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Treatment with baricitinib (bari), an oral inhibitor of JAK1/JAK2, demonstrated improvements in signs and symptoms of RA through 52 wks in a Phase 2b…
Abstract Number: 489 • 2014 ACR/ARHP Annual Meeting
Rosuvastatin Improves Arterial Stiffness in Patients with Inflammatory Joint Diseases
Eirik Ikdahl¹, Silvia Rollefstad¹, Jonny Hisdal², Inge C. Olsen³, Ingar Holme⁴, Terje R. Pedersen⁵, Tore Kvien⁶ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of biostatistics, epidemiology and health economics, Oslo University Hospital, Oslo, Norway, ⁵Faculty of Medicine, University of Oslo, Oslo, Norway, ⁶Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose Arterial stiffness, as pulse wave velocity (PWV) and augmentation index (AIx) has emerged as early risk markers of cardiovascular disease (CVD) in patients with…
Abstract Number: 487 • 2014 ACR/ARHP Annual Meeting
Assessment of Lipid Changes in Patients with Early Rheumatoid Arthritis Treated with Tofacitinib or Methotrexate over 24 Months
C. Charles-Schoeman¹, A. Dikranian², J. Taylor³, B. Wilkinson⁴, T. Jones⁵, K. Kwok⁶ and C. Nduaka⁴, ¹University of California, Los Angeles, CA, ²San Diego Arthritis Medical Clinic, San Diego, CA, ³Anderson Arthritis and Rheumatology Center, Meridian, MS, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) increases in mean low-density lipoprotein cholesterol (LDL-C) and…
Abstract Number: 486 • 2014 ACR/ARHP Annual Meeting
Tofacitinib Improves Arterial Stiffness Despite up-Regulating Serum Cholesterol with Chronic Cardiovascular Disease in Methotrexate-Resistant Active Rheumatoid Arthritis Patients. a Cohort Study
Kensuke Kume¹, Kanzo Amano², Susumu Yamada², Toshikatsu Kanazawa³, Hiroshi Komori⁴, Kazuhiko Hatta⁵, Kuniki Amano⁶ and Noriko Kuwaba⁷, ¹20-16 Higashi Kannon, Nishi Ward, hiroshima clinic, Hiroshima, Japan, ²Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴internal medicine, hiroshima clinic, hiroshima, Japan, ⁵Rheumatology, Hatta Clinic, Kure, Japan, ⁶Rheumatology, Sky Clinic, Hiroshima, Japan, ⁷Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk. We should have strategies for primary cardiovascularprevention in RA. Tofacitinib (Tofa) could possibly…
Abstract Number: 462 • 2014 ACR/ARHP Annual Meeting
Infections and Gastrointestinal Side Effects in a Comparison of Rheumatoid Arthritis Therapies
Bei-Hung Chang^1,2, Lien Quach¹, Mary Brophy³, Keri Hannagan⁴, Edward C. Keystone⁵, Ted R. Mikuls⁶ and James R. O'Dell⁷, ¹VA Boston Healthcare System, Boston, MA, ²Qualitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, ³VA Boston Heathcare System, Boston, MA, ⁴MAVERIC, VA Boston Heathcare System, Boston, MA, ⁵Medicine, University of Toronto, Toronto, ON, Canada, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁷Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose TNF inhibitors and combinations of conventional disease-modifying antirheumatic drugs are commonly added to treat methotrexate non-responsive rheumatoid arthritis patients. In the 48-week double blind,…
Abstract Number: 461 • 2014 ACR/ARHP Annual Meeting
Comprehensive Summary of the Efficacy and Safety of Tofacitinib 5mg Twice Daily in Patients with Rheumatoid Arthritis and an Inadequate Response to Disease-Modifying Antirheumatic Drugs
P. Bird¹, W. Bensen², B. El-Zorkany³, J. Kaine⁴, B.H. Manapat-Reyes⁵, V. Pascual-Ramos⁶, D. Witcombe⁷, A. Anisfeld⁸, K. Soma⁹, R. Zhang⁹ and K. Thirunavukkarasu⁷, ¹Combined Rheumatology Practice, Sydney, Australia, ²St. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada, ³Department of Rheumatology, Cairo University, Cairo, Egypt, ⁴Sarasota Arthritis Research Center, Sarasota, FL, ⁵Section of Rheumatology, Department of Medicine, University of the Philippines - Philippine General Hospital, Manila, Philippines, ⁶Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁷Pfizer Australia, Sydney, Australia, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib has been approved in the US and other countries at the recommended dose 5 mg BID in patients (pts) with rheumatoid arthritis (RA) and…
Abstract Number: 460 • 2014 ACR/ARHP Annual Meeting
Analysis of Non-Melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Program
Jeffrey R. Curtis¹, E.B. Lee², G. Martin³, X. Mariette⁴, K.K. Terry⁵, Y. Chen⁶, J. Geier⁷, J. Andrews⁵, M. Kaur⁶, K. Kwok⁷ and C. Nduaka⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Seoul National University College of Medicine, Seoul, South Korea, ³Dermatology and Laser Center of Maui, Kihei, HI, ⁴Paris-Sud University, Paris, France, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The incidence of non-melanoma skin cancer (NMSC) in the tofacitinib…
Abstract Number: 459 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Effect of Tofacitinib on Measured Glomerular Filtration Rate in Patients with Active Rheumatoid Arthritis
J. Kremer¹, A.J. Kivitz², J.a. Simon Campos³, E.L. Nasonov⁴, H. Tony⁵, B. Vlahos⁶, C. Hammond⁶, J. Bukowski⁶, H. Li⁶, S. Schulman⁶, S. Raber⁷, A. Zuckerman⁸ and J. Isaacs⁹, ¹Albany Medical College and The Center for Rheumatology, Albany, NY, ²Altoona Center for Clinical Research, Duncansville, PA, ³Hospital CEM/BIOCEM, Merida, Mexico, ⁴Nasonova State Institute of Rheumatology, Moscow, Russia, ⁵University Hospital Würzburg, Würzburg, Germany, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, San Diego, CA, ⁸Pfizer Inc, Groton, CT, ⁹National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom
Background/Purpose: In the clinical development program of the oral Janus kinase inhibitor tofacitinib for the treatment of rheumatoid arthritis (RA), small mean increases in serum…
Abstract Number: 478 • 2014 ACR/ARHP Annual Meeting
Adverse Events and Infections in Patients with Rheumatoid Arthritis Treated with Conventional Drugs or Biologic Agents: A Real World Study
Christos E. Lampropoulos¹, Philippos Orfanos², Vasiliki-Kalliopi Bournia³, Theofilos P. Karatsourakis⁴, Clio P. Mavragani⁵, Dimitrios Pikazis⁴, Menelaos N. Manoussakis⁶, Athanasios G. Tzioufas⁴, Haralampos M. Moutsopoulos⁷ and Panayiotis G. Vlachoyiannopoulos³, ¹Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ²Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National University of Athens, Athens, Greece, ³First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ⁴Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ⁵Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, ⁶Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ⁷Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease with joint destruction and permanent disability. Biologic agents (BAs) offer a better outcome when disease is…
Abstract Number: 477 • 2014 ACR/ARHP Annual Meeting
Leflunomide Use Is Not Associated with an Increased Risk of Lung Disease in Rheumatoid Arthritis: A Meta-Analysis of Randomised Controlled Trials
Richard Conway¹, Candice Low², Robert J. Coughlan¹, Martin O'Donnell³ and John J. Carey¹, ¹Rheumatology, Galway University Hospitals, Galway, Ireland, ²Medicine, St. James Hospital, Dublin, Ireland, ³Clinical Research Facility, Galway University Hospitals, Galway, Ireland
Background/Purpose Leflunomide is an effective treatment for rheumatoid arthritis. An association between pulmonary adverse events, in particular interstitial lung disease, and leflunomide use has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].